The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShire Share News (SHP)

  • There is currently no data for SHP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Sumitomo Dainippon Pharma investing $3 bln in Swiss Roivant in overseas push

Fri, 06th Sep 2019 07:54

* Dainippon to buy 10% stake in Roivant and interests in 5units

* Schizophrenia treatment Latuda to lose US exclusivity in2023

* Japan pharma firms grapple with declining population athome(Adds Dainippon CEO comment, context and stock price)

By Rocky Swift

TOKYO, Sept 6 (Reuters) - Japan's Sumitomo Dainippon PharmaCo will pay $3 billion for a 10% stake in Swissdrugmaker Roivant Sciences Ltd and interests in five of itsbiopharmaceutical businesses, the two companies said on Friday.

The deal, which will open up new drug lines for SumitomoDainippon, will also give it the option to acquire interests inan additional six businesses, as well as access to Roivant'stechnology platforms, they said in a statement.

It comes as Sumitomo Dainippon's schizophrenia treatmentLatuda is due to lose its U.S. market exclusivity in 2023. TheJapanese company will take ownership of Roivant units thatdevelop treatments for prostate cancer, urinary diseases,pediatric illnesses and respiratory diseases, they said.

"We look forward to deepening our relationship with Roivant,which has a rich development pipeline, technology platforms, anddistinctive talents," Sumitomo Dainippon CEO Hiroshi Nomura saidin the statement.

Like its rivals, Japan's seventh-largest pharma company byrevenue, is grappling with a declining population at home and aneed to go abroad to find growth.

While the bulk of Japanese drug firms have been largelycautious about overseas acquisitions, there are signs of change.Takeda Pharmaceutical this year completed a $59 billionpurchase of Shire Plc, catapulting it into the list of theworld's top 10 drugmakers by sales - a rarity for a Japanesepharma company.

A fifth Roivant business unit will also be transferredbefore the deal's conclusion, the two companies said.

The 11 businesses include more than 25 clinical programswith multiple product launches expected between 2020 and 2022,they said.

Shares of Sumitomo Dainippon finished up 1.7% at 1,800 yenon Friday.(Reporting by Rocky Swift; Editing by David Dolan andMuralikumar Anantharaman)

More News
24 Aug 2018 11:54

LONDON MARKET MIDDAY: Stocks Up; Powell To Make Jackson Hole Debut

LONDON (Alliance News) - Stocks in London were marginally higher at midday on Friday ahead of a highly anticipated speech from the head of the US Federal Reserve.With US-China trade talks demoting a

Read more
24 Aug 2018 10:39

WINNERS & LOSERS SUMMARY: Shire Rises As US FDA Approves Takhzyro Drug

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.----------FTSE 100 - up 2.6%. The Irish pharmaceutical company said a

Read more
24 Aug 2018 08:38

LONDON MARKET OPEN: Stocks Mixed, Shire Rises After Drug Approval

LONDON (Alliance News) - Stock prices in London were mixed early Friday, as markets await US Federal Reserve Chair Jerome Powell's speech in Wyoming later in the day. In the large cap index rose

Read more
24 Aug 2018 08:06

FDA gives nod to Shire's TAKHZYRO treatment

(Sharecast News) - Shire announced on Friday that, following priority review, the US Food and Drug Administration (FDA) has approved the 'TAKHZYRO' (lanadelumab-flyo) injection for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years of age and older.

Read more
24 Aug 2018 07:41

LONDON MARKET PRE-OPEN: Slightly Lower Call Ahead Of Powell Speech

LONDON (Alliance News) - Stock prices in London are seen lower on Friday ahead of US Federal Reserve Chair Jerome Powell's speech later during the day, while in a quiet day for UK company news In

Read more
13 Aug 2018 10:31

WINNERS & LOSERS SUMMARY: Chemring Says Fatal Accident To Hurt Profit

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------BAE up 0.8%. a

Read more
13 Aug 2018 09:21

Shire Partner Shionogi Files New Drug Application For Intuniv In Japan

LONDON (Alliance News) - Irish drugmaker Shire PLC said on Monday its Japanese partner Shionogi & Co Ltd has submitted a new drug application for the manufacture and marketing of Intuniv in is

Read more
13 Aug 2018 07:51

Shire and Shionogi apply to expand ADHD treatment to adults

(Sharecast News) - Shire and Shionogi have applied to expand the use in Japan of co-developed drug Intuniv to treat adults for attention deficit hyperactivity disorder.

Read more
31 Jul 2018 12:51

TOP NEWS: Shire Income Up In 2nd-Quarter Ahead Of Takeover By Takeda

LONDON (Alliance News) - Irish biotechnology company Shire PLC on Tuesday posted a more than doubled pretax income in the second quarter, ahead of its upcoming takeover by Takeda Pharmaceutical Co

Read more
31 Jul 2018 12:12

Shire posts 4 pct rise in Q2 earnings ahead of sale to Takeda

LONDON, July 31 (Reuters) - Shire, the London-listed pharmaceutical group being bought by Japan's Takeda, reported a 4 percent rise in second-quarter earnings as revenue rose 5 percent to just

Read more
31 Jul 2018 12:08

Shire's quarterly sales rise on immunology demand

(Sharecast News) - Shire reported healthy sales growth in the second quarter as the biotech company pressed ahead with its acquisition by Takeda of Japan.

Read more
31 Jul 2018 08:05

UPDATE 1-Takeda posts weakest Q1 profit in three years

* Q1 operating profit Y98.9 bln vs Y195 bln a year earlier * Takeda booked gains from asset sales a year earlier (Adds details) TOKYO, July 31 (Reuters) - Japan's Takeda Co Ltd a

Read more
25 Jul 2018 07:00

RPT-ANALYSIS-Buy yen in crisis? Not this year

* Yen weakest G10 currency this month despite global turbulence * Investors doubt BOJ can reduce stimulus aggressively * Japanese purchases of foreign equities highest in nearly Bond

Read more
24 Jul 2018 16:06

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 25 July GlaxoSmithKlineHalf Year Results (at 1200 BST)Vodafone GroupTrading 26

Read more
24 Jul 2018 15:08

ANALYSIS-Buy yen in crisis? Not this year

* Yen weakest G10 currency this month despite global turbulence * Investors doubt BOJ can reduce stimulus aggressively * Japanese purchases of foreign equities highest in nearly Bond

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.